-
公开(公告)号：US10435414B2
公开(公告)日：2019-10-08
申请号：US16044862
申请日：2018-07-25
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: A61K31/4188 , A61K31/424 , A61K31/498 , A61K31/5365 , A61K45/06 , C07D498/04 , C07D498/06 , C07D519/00 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/5383 , A61K31/553 , C07D491/044
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US20170233407A1
公开(公告)日：2017-08-17
申请号：US15374867
申请日：2016-12-09
Applicant: Genentech, Inc.
Inventor： Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
IPC: C07D498/22 , A61K31/5377 , C07K16/22 , A61K39/395 , C07D495/14 , A61K31/5383 , C07D471/14 , C07D487/14 , A61K31/5386 , C07D491/147 , C07D498/14
Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
-
公开(公告)号：US20220348593A1
公开(公告)日：2022-11-03
申请号：US17535124
申请日：2021-11-24
Applicant: Genentech, Inc.
Inventor： Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
IPC: C07D498/22 , C07D471/14 , C07D491/14 , C07D495/14 , C07D487/14 , C07D498/14 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/395 , C07D491/147 , C07D498/20 , C07K16/22
Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
-
公开(公告)号：US20180327420A1
公开(公告)日：2018-11-15
申请号：US16044862
申请日：2018-07-25
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Keira Garland , Emily Hanan , Hans Purkey , Steven T. Staben , Robert Andrew Heald , Jamie Knight , Calum Macleod , Aijun Lu , Guosheng Wu , Siew Kuen Yeap
IPC: C07D498/04 , C07D519/00 , C07D498/06 , A61K31/5365 , A61K31/4188 , A61K31/498 , A61K31/4196 , C07D491/044 , A61K31/428 , A61K31/4439 , A61K31/5383 , A61K31/553 , A61K45/06 , A61K31/423
CPC classification number: C07D498/04 , A61K31/4188 , A61K31/4196 , A61K31/423 , A61K31/428 , A61K31/4439 , A61K31/498 , A61K31/5365 , A61K31/5383 , A61K31/553 , A61K45/06 , C07D491/044 , C07D498/06 , C07D519/00
Abstract: Described herein are tricyclic compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US20170210733A1
公开(公告)日：2017-07-27
申请号：US15481764
申请日：2017-04-07
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: C07D413/14 , C07D267/08
CPC classification number: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
-
Patent Agency Ranking
公开(公告)号：US09643980B2
公开(公告)日：2017-05-09
申请号：US15200307
申请日：2016-07-01
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: A61K31/553 , C07D498/04 , C07D498/14 , C07D519/00 , A61K45/06
CPC classification number: C07D498/04 , A61K31/553 , A61K45/06
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation.
-
公开(公告)号：US09546182B2
公开(公告)日：2017-01-17
申请号：US14524204
申请日：2014-10-27
Applicant: Genentech, Inc.
Inventor： Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQuing Wei
IPC: C07D471/14 , C07D471/22 , C07D487/14 , C07D498/14 , C07D491/14 , C07D495/14 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/395 , C07D491/147 , C07D498/20 , A61K39/00
CPC classification number: C07D498/22 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/3955 , A61K2039/505 , C07D471/14 , C07D471/22 , C07D487/14 , C07D491/14 , C07D491/147 , C07D495/14 , C07D498/14 , C07D498/20 , C07K16/22 , C07K2317/24
Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
Abstract translation: 式I化合物包括立体异构体，几何异构体，互变异构体及其药学上可接受的盐。 虚线表示可选的双键，至少一条虚线是双键。 取代基如所述。
-
公开(公告)号：US20150079081A1
公开(公告)日：2015-03-19
申请号：US14524204
申请日：2014-10-27
Applicant: Genentech, Inc.
Inventor： Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQuing Wei
IPC: C07D498/14 , A61K31/5377 , A61K31/5386 , A61K31/5383 , C07D498/20 , C07D491/147 , A61K39/395
CPC classification number: C07D498/22 , A61K31/5377 , A61K31/5383 , A61K31/5386 , A61K39/3955 , A61K2039/505 , C07D471/14 , C07D471/22 , C07D487/14 , C07D491/14 , C07D491/147 , C07D495/14 , C07D498/14 , C07D498/20 , C07K16/22 , C07K2317/24
Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
Abstract translation: 描述了具有抗癌活性，抗炎活性或免疫调节特性，更具体地与PI3激酶调节或抑制活性的式I的三环PI3k抑制剂化合物。 描述了使用式I的三环PI3K抑制剂化合物用于体外，原位和体内诊断或治疗哺乳动物细胞，生物体或相关病理条件的方法。 式I化合物包括立体异构体，几何异构体，互变异构体及其药学上可接受的盐。 虚线表示可选的双键，至少一条虚线是双键。 取代基如所述。
-
公开(公告)号：US20190330235A1
公开(公告)日：2019-10-31
申请号：US16507523
申请日：2019-07-10
Applicant: Genentech, Inc.
Inventor： Jennafer Dotson , Robert Andrew Heald , Timothy Heffron , Graham Elgin Jones , Sussie Lerche Krintel , Neville James McLean , Chudi Ndubaku , Alan G. Olivero , Laurent Salphati , Lan Wang , BinQing Wei
IPC: C07D498/22 , C07D498/20 , A61K31/5377 , C07D471/14 , C07D498/14 , A61K31/5383 , A61K31/5386 , A61K39/395 , C07D491/147 , C07D495/14 , C07D491/14 , C07D487/14 , C07K16/22
Abstract: Tricyclic PI3k inhibitor compounds of Formula I with anti-cancer activity, anti-inflammatory activity, or immunoregulatory properties, and more specifically with PI3 kinase modulating or inhibitory activity are described. Methods are described for using the tricyclic PI3K inhibitor compounds of Formula I for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, organisms, or associated pathological conditions. Formula I compounds include stereoisomers, geometric isomers, tautomers, and pharmaceutically acceptable salts thereof. The dashed lines indicate an optional double bond, and at least one dashed line is a double bond. The substituents are as described.
-
公开(公告)号：US20180127404A1
公开(公告)日：2018-05-10
申请号：US15729507
申请日：2017-10-10
Applicant: Genentech, Inc.
Inventor： Marie-Gabrielle Braun , Emily Hanan , Steven T. Staben , Robert Andrew Heald , Calum MacLeod , Richard Elliott
IPC: C07D413/14 , C07D267/08
CPC classification number: C07D413/14 , A61K31/553 , C07D267/08 , C07D498/04
Abstract: Described herein are benzoxazepin oxazolidinone compounds with phosphoinositide-3 kinase (PI3K) modulation activity or function having the Formula I structure: or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such PI3K modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon PI3K dysregulation. Also described are methods of making the benzoxazepin oxazolidinone compounds having the Formula I structure.
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.033 seconds)
